journal article·2022-09-28

Combined Chemo–Immuno–Photothermal Therapy for Effective Cancer Treatment via an All-in-One and One-for-All Nanoplatform

Xianglong Yu, Ning Han, Ziyi Dong, Yunni Dang, Qing Zhang, Wenjun Hu, Changhai Wang, Shouying Du, Yang Lu

ACS Applied Materials & Interfaces· Volume 14· Issue 38
Publisher page

Abstract

Tumor metastasis and recurrence are recognized to be the main causes of failure in cancer treatment. To address these issues, an “all in one” and “one for all” nanoplatform was established for combined “chemo–immuno–photothermal” therapy with the expectation to improve the antitumor efficacy. Herein, Docetaxel (DTX, a chemo-agent) and cynomorium songaricum polysaccharide (CSP, an immunomodulator) were loaded into zein nanoparticles coated by a green tea polyphenols/iron coordination complex (GTP/FeIII, a photothermal agent). From the result, the obtained nanoplatform denoted as DTX-loaded Zein/CSP-GTP/FeIII NPs was spherical in morphology with an average particle size of 274 nm, and achieved pH-responsive drug release. Moreover, the nanoplatform exhibited excellent photothermal effect both in vitro and in vivo. It was also observed that the nanoparticles could be effectively up take by tumor cells and inhibited their migration. From the results of the in vivo experiment, this nanoplatform could completely eliminate the primary tumors, prevent tumor relapses on LLC (Lewis lung cancer) tumor models, and significantly inhibit metastasis on 4T1 (murine breast cancer) tumor models. The underlying mechanism was also explored. It was discovered that this nanoplatform could induce a strong ICD effect and promote the release of damage-associated molecular patterns (DAMPs) including CRT, ATP, and HMGB1 by the dying tumor cells. And the CSP could assist the DAMPs in inducing the maturation of dendritic cells (DCs) and facilitate the intratumoral infiltration of T lymphocytes to clear up the residual or disseminated tumor cells. In summary, this study demonstrated that the DTX-loaded Zein/CSP-GTP/FeIII is a promising nanoplatform to completely inhibit tumor metastasis and recurrence.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Beijing University of Chinese Medicine, Number 11 east Section of the North Third Ring Road, Beijing 100029, China

Funding

Beijing University of Chinese Medicine · National Natural Science Foundation of China

References (71)

Show source-provided references
1. 10.1021/acsnano.7b0473610.1021/acsnano.7b04736 ↗
2. 10.1586/14737140.5.1.1310.1586/14737140.5.1.13 ↗
3. 10.3390/pr907108610.3390/pr9071086 ↗
4. 10.1016/j.bbcan.2020.18848110.1016/j.bbcan.2020.188481 ↗
5. 10.7536/PC18063010.7536/PC180630 ↗
6. 10.2147/IJN.S4692110.2147/IJN.S46921 ↗
7. 10.1080/10717544.2019.170494210.1080/10717544.2019.1704942 ↗
8. 10.1177/175883592098036510.1177/1758835920980365 ↗
9. 10.1016/j.jconrel.2020.06.03210.1016/j.jconrel.2020.06.032 ↗
10. 10.1016/j.biomaterials.2014.07.06410.1016/j.biomaterials.2014.07.064 ↗
11. 10.1021/acsnano.8b0145610.1021/acsnano.8b01456 ↗
12. 10.1039/D1BM00474C10.1039/D1BM00474C ↗
13. 10.1002/adhm.20150089810.1002/adhm.201500898 ↗
14. 10.1021/acsbiomaterials.6b0049710.1021/acsbiomaterials.6b00497 ↗
15. 10.1021/acsnano.0c0077110.1021/acsnano.0c00771 ↗
16. 10.1021/acsnano.5b0727610.1021/acsnano.5b07276 ↗
17. 10.1039/C4NR00617H10.1039/C4NR00617H ↗
18. 10.3389/fimmu.2018.0114910.3389/fimmu.2018.01149 ↗
19. 10.3390/cells906147410.3390/cells9061474 ↗
20. 10.1021/acsnano.8b0189010.1021/acsnano.8b01890 ↗
21. 10.1002/1878-0261.1285110.1002/1878-0261.12851 ↗
22. 10.1021/acsami.9b1713710.1021/acsami.9b17137 ↗
23. 10.1002/mabi.20210042910.1002/mabi.202100429 ↗
24. 10.2147/IJN.S31450610.2147/IJN.S314506 ↗
25. 10.1038/s41401-020-0400-z10.1038/s41401-020-0400-z ↗
26. 10.2147/IJN.S24644710.2147/IJN.S246447 ↗
27. 10.1016/j.carbpol.2014.11.04810.1016/j.carbpol.2014.11.048 ↗
28. 10.3389/fimmu.2020.0090410.3389/fimmu.2020.00904 ↗
29. 10.1080/10408398.2015.107719110.1080/10408398.2015.1077191 ↗
30. 10.3109/13880209.2012.65811410.3109/13880209.2012.658114 ↗
31. 10.1016/j.biomaterials.2017.06.00710.1016/j.biomaterials.2017.06.007 ↗
32. 10.2147/IJN.S24925210.2147/IJN.S249252 ↗
33. 10.1166/jbt.2021.273610.1166/jbt.2021.2736 ↗
34. 10.1016/j.carbpol.2020.11697010.1016/j.carbpol.2020.116970 ↗
35. 10.1021/acs.jafc.0c0263210.1021/acs.jafc.0c02632 ↗
36. 10.1021/acs.langmuir.9b0119610.1021/acs.langmuir.9b01196 ↗
37. 10.2147/IJN.S13085910.2147/IJN.S130859 ↗
38. 10.1002/smll.20180234210.1002/smll.201802342 ↗
39. 10.3390/pharmaceutics1112063610.3390/pharmaceutics11120636 ↗
40. 10.1039/D0TB00008F10.1039/D0TB00008F ↗
41. 10.1016/j.biomaterials.2016.04.04110.1016/j.biomaterials.2016.04.041 ↗
42. 10.1002/chem.20190314510.1002/chem.201903145 ↗
43. 10.1016/j.carbpol.2019.04.04110.1016/j.carbpol.2019.04.041 ↗
44. 10.1021/am508404t10.1021/am508404t ↗
45. 10.1039/C4NR00617H10.1039/C4NR00617H ↗
46. 10.1016/j.ijbiomac.2012.07.01910.1016/j.ijbiomac.2012.07.019 ↗
47. 10.1007/s11426-016-5593-010.1007/s11426-016-5593-0 ↗
48. 10.3389/fphar.2020.0079210.3389/fphar.2020.00792 ↗
49. 10.1021/nn505468v10.1021/nn505468v ↗
50. 10.1002/wnan.161210.1002/wnan.1612 ↗
51. 10.1016/j.bioactmat.2020.08.02410.1016/j.bioactmat.2020.08.024 ↗
52. 10.3389/fbioe.2020.0048810.3389/fbioe.2020.00488 ↗
53. 10.3390/cells1002023110.3390/cells10020231 ↗
54. 10.1016/j.carbpol.2020.11718710.1016/j.carbpol.2020.117187 ↗
55. 10.1016/j.nano.2016.08.01710.1016/j.nano.2016.08.017 ↗
56. 10.1021/acsami.9b1174610.1021/acsami.9b11746 ↗
57. 10.1021/acsnano.0c0665610.1021/acsnano.0c06656 ↗
58. 10.1021/acsnano.1c0897810.1021/acsnano.1c08978 ↗
59. 10.3389/fimmu.2021.81028610.3389/fimmu.2021.810286 ↗
60. 10.1093/intimm/dxaa07810.1093/intimm/dxaa078 ↗
61. 10.1016/j.cbi.2019.05.01710.1016/j.cbi.2019.05.017 ↗
62. 10.3109/01480545.2011.59853110.3109/01480545.2011.598531 ↗
63. 10.1016/j.biopha.2017.10.15810.1016/j.biopha.2017.10.158 ↗
64. 10.1002/advs.20210344410.1002/advs.202103444 ↗
65. 10.1002/adma.20200742610.1002/adma.202007426 ↗
66. 10.1021/acs.nanolett.0c0477810.1021/acs.nanolett.0c04778 ↗
67. 10.11777/j.issn1000-3304.2021.2111510.11777/j.issn1000-3304.2021.21115 ↗
68. 10.1021/acsami.1c1478110.1021/acsami.1c14781 ↗
69. 10.1016/j.jconrel.2019.12.04210.1016/j.jconrel.2019.12.042 ↗
70. 10.1016/j.msec.2019.11010310.1016/j.msec.2019.110103 ↗
71. 10.1016/j.apmt.2019.10052110.1016/j.apmt.2019.100521 ↗